RT Journal Article
SR Electronic
T1 <sup>89</sup>Zr-Labeled Versus <sup>124</sup>I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1112
OP 1118
DO 10.2967/jnumed.114.149690
VO 56
IS 7
A1 Claudia T. Mendler
A1 Torben Gehring
A1 Hans-Jürgen Wester
A1 Markus Schwaiger
A1 Arne Skerra
YR 2015
UL http://jnm.snmjournals.org/content/56/7/1112.abstract
AB Immuno-PET imaging of the tumor antigen HER2/neu allows for the noninvasive detection and monitoring of oncogene expression; such detection and monitoring are of prognostic value in patients with breast cancer. Compared with the full-size antibody trastuzumab, smaller protein tracers with more rapid blood clearance permit higher imaging contrast at earlier time points. Antigen-binding fragments (Fabs) of antibodies with moderately prolonged circulation achieved through the genetic fusion with a long, conformationally disordered chain of the natural amino acids Pro, Ala, and Ser (PASylation)—a biologic alternative to chemical conjugation with polyethylene glycol, PEG—offer a promising tracer format with improved pharmacokinetics for in vivo imaging. Recently, the transition metal radionuclide 89Zr has attracted increasing interest for immuno-PET studies, complementing the conventional halogen radionuclide 124I. Methods: To allow direct comparison of these 2 radioactive labels for the same protein tracer, the recombinant αHER2 Fab fused with 200 Pro, Ala, and Ser (PAS200) residues was either conjugated with 124I via an iodination reagent or coupled with deferoxamine (Df) and complexed with 89Zr. After confirmation of the stability of both radioconjugates and quality control in vitro, immuno-PET and biodistribution studies were performed with CD1-Foxn1nu mice bearing HER2-positive human tumor xenografts. Results: 89Zr⋅Df-Fab-PAS200 and 124I-Fab-PAS200 showed specific tumor uptake of 11 and 2.3 percentage injected dose per gram 24 h after injection, respectively; both led to high tumor-to-blood (3.6 and 4.4, respectively) and tumor-to-muscle (20 and 43, respectively) ratios. With regard to off-target accumulation, overt 124I activity was seen in the thyroid, as expected, whereas high kidney uptake was evident for 89Zr; the latter was probably due to glomerular filtration and reabsorption of the protein tracer in proximal tubular cells. Conclusion: Both 89Zr- and 124I-labeled versions of αHER2 Fab-PAS200 allowed PET tumor imaging with high contrast. With its residualizing radiometal, the tracer 89Zr⋅Df-Fab-PAS200 showed better in vivo stability and higher tumor uptake.